Initiate the 755-201-EB clinical trial in multiple European jurisdictions
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- September 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiate 755 - 201 - EB trial in multiple European jurisdictions”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 2 clinical trial (755-201-EB) in September 2021, which involved multiple sites across several countries.
-
A InMed Pharmaceuticals Inc. 8-K filed 2022-01-05
“Phase 2 efficacy trial, which we initiated in September of 2021.” ✓ confirmed on the page
-
A InMed Pharmaceuticals Inc. 8-K filed 2022-01-05
“The Phase 2 study will be enrolling and treating EB patients at thirteen targeted sites across multiple countries throughout 2022.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- 755-201-EB clinical trial
- Where
- Europe
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you InMed Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-INM-021654 · Corrections policy